Paper of the Month - Volume 33 Issue 1

0 rating

Novel Biomarkers and Myositis-Specific Autoantibodies in the Management of Idiopathic Inflammatory Myopathies

Floranne C Ernste, MD, and Ann M Reed, MD

The idiopathic inflammatory myopathies (IIMs) are a group of rare, inflammatory muscle disorders characterized by muscle weakness, elevated muscle enzymes, and extramuscular system involvement, such as fever, rash, and interstitial lung disease (ILD). The main subsets of IIM are adult dermatomyositis (DM), juvenile DM (JDM), polymyositis (PM), and inclusion body myositis (IBM). Each of these subtypes is classified based on distinct immuno-histopathological features on cutaneous and/or muscle biopsies [1–3]. The International Myositis Assessment and Clinical Studies Group and the Paediatric Rheumatology International Trials Organisation have a preliminary core set of measures to assess disease activity, disease damage, extramuscular organ involvement, perform-ance of activities of daily living, and quality of life in adults and children with IIM [4–6].



READER POLL

Rheum poll 1
Which of the following tests for latent TB infection do you initially perform prior to starting anti-TNF or other immunosuppressive therapies in your patients?






Powered by NetPolls

SUBMIT AN ARTICLE